gsk256073
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00488449)
Timeline
Indications
Mechanism of action
HCAR2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 8-chloro-3-pentyl-1h-purine-2,6(3h,7h)-dione
- gsk256073
- gsk256073
- gsk256073
- gsk256073a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01376323 | Phase 2 | Jul 1, 2011 | GlaxoSmithKline |
| NCT01147861 | Phase 1 | Jul 1, 2010 | GlaxoSmithKline |
| NCT00903617 | Phase 2 | Jun 1, 2009 | GlaxoSmithKline |
| NCT00808093 | Phase 1 | May 12, 2008 | GlaxoSmithKline |
| NCT00608699 | Phase 1 | Dec 1, 2007 | GlaxoSmithKline |
| NCT00551694 | Phase 1 | Oct 1, 2007 | GlaxoSmithKline |
| NCT00488449 | Phase 1 | Jun 1, 2007 | GlaxoSmithKline |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 7 | 7 | 2 | 2007 |
1 organizations
Page 1 / 1